HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.

RETEVMO® (selpercatinib) capsules, for oral use
RETEVMO® (selpercatinib) tablets, for oral use
Initial U.S. Approval: 2020

RETEVMO® is a kinase inhibitor indicated for the treatment of:

- Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test (1.1)
- Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy1 (1.2)
- Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)1 (1.3)
- Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options1 (1.4)

1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

INDICATIONS AND USAGE
Select patients for treatment with RETEVMO based on the presence of a RET gene fusion (NSCLC, thyroid, or other solid tumors) or specific RET gene mutation (MTC). (2.1, 14)

Recommended dosage in adults and pediatric patients 12 years of age or older is based on weight (2.3):
- Less than 50 kg: 120 mg orally twice daily
- 50 kg or greater: 160 mg orally twice daily

Reduce RETEVMO dose in patients with severe hepatic impairment. (2.7, 8.7)

DOSAGE FORMS AND STRENGTHS
- Capsules: 40 mg, 80 mg (3)
- Tablets: 40 mg, 80 mg, 120 mg, 160 mg (3)

CONTRAINDICATIONS
None. (4)

WARNINGS AND PRECAUTIONS
- Hepatotoxicity: Monitor ALT and AST prior to initiating RETEVMO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue RETEVMO based on severity. (2.5, 5.1)
- Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening pulmonary symptoms. Withhold, reduce the dose or permanently discontinue RETEVMO based on severity. (2.5, 5.2)
- Hypertension: Do not initiate RETEVMO in patients with uncontrolled hypertension. Optimize blood pressure (BP) prior to initiating RETEVMO. Monitor BP after 1 week, at least monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue RETEVMO based on severity. (2.5, 5.3)
- QT Interval Prolongation: Monitor patients who are at significant risk of developing QTc prolongation. Assess QT interval, electrolytes and TSH at baseline and periodically during treatment. Monitor QT interval more frequently when RETEVMO is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and dose reduce or permanently discontinue RETEVMO based on severity. (2.5, 5.4)
- Hemorrhagic Events: Permanently discontinue RETEVMO in patients with severe or life-threatening hemorrhage. (2.5, 5.5)
- Hypersensitivity: Withhold RETEVMO and initiate corticosteroids. Upon resolution, resume at a reduced dose and increase dose by 1 dose level each week until reaching the dose taken prior to onset of hypersensitivity. Continue steroids until patient reaches target dose and then taper. (2.5, 5.6)
- Tumor Lysis Syndrome: Closely monitor patients at risk and treat as clinically indicated. (5.7)
- Risk of Impaired Wound Healing: Withhold RETEVMO for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of RETEVMO after resolution of wound healing complications has not been established. (5.8)
- Hypothyroidism: Monitor thyroid function before treatment with RETEVMO and periodically during treatment. Withhold until clinically stable or permanently discontinue based on severity. (5.9)
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the possible risk to a fetus and to use effective contraception. (5.10, 8.1, 8.3)

ADVERSE REACTIONS
The most common adverse reactions (≥25%) were edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache. (6)

The most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), decreased sodium, and decreased calcium. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-Lilly Rx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
- Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2.4, 7.1)
- Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2.6, 7.1)
- Strong and Moderate CYP3A Inducers: Avoid coadministration. (7.1)
- CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7.2)
- Certain P-gp Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7.2)

USE IN SPECIFIC POPULATIONS
- Lactation: Advise not to breastfeed. (8.2)
- Pediatric Use: Monitor open growth plates in adolescent patients. Consider interrupting or discontinuing RETEVMO if abnormalities occur. (8.4)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 04/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.1 RET Fusion-Positive Non-Small Cell Lung Cancer
1.2 RET-Mutant Medullary Thyroid Cancer
1 INDICATIONS AND USAGE

1.1 RET Fusion-Positive Non-Small Cell Lung Cancer

RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.

1.2 RET-Mutant Medullary Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.

This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

1.3 RET Fusion-Positive Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.3)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

1.4 Other RET Fusion-Positive Solid Tumors

RETEVMO is indicated for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

7.1 Effects of Other Drugs on RETEVMO

7.2 Effects of RETEVMO on Other Drugs

7.3 Drugs that Prolong QT Interval

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 RET Fusion-Positive Non-Small Cell Lung Cancer

14.2 RET-Mutant Medullary Thyroid Cancer

14.3 RET Fusion-Positive Thyroid Cancer

14.4 Other RET Fusion-Positive Solid Tumors

* Sections or subsections omitted from the full prescribing information are not listed.
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.4)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection
Select patients for treatment with RETEVMO based on the presence of a RET gene fusion (NSCLC, thyroid cancer, or other solid tumors) or specific RET gene mutation (MTC) in tumor specimens [see Clinical Studies (14)]. Information on FDA-approved test(s) for the detection of RET gene fusions and RET gene mutations is available at: http://www.fda.gov/CompanionDiagnostics. An FDA-approved companion diagnostic test for the detection of RET gene fusions and RET gene mutations in plasma or in tumors other than NSCLC and thyroid cancer is not currently available.

2.2 Important Administration Instructions
RETEVMO may be taken with or without food unless coadministered with a proton pump inhibitor (PPI) [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].

2.3 Recommended Dosage
The recommended dosage of RETEVMO, based on body weight, is:

- Less than 50 kg: RETEVMO 120 mg taken orally twice daily with or without food
- 50 kg or greater: RETEVMO 160 mg taken orally twice daily with or without food

Continue treatment with RETEVMO until disease progression or unacceptable toxicity.

Swallow the capsules whole. Do not crush or chew the capsules.

Swallow the tablets whole. Do no crush or chew the tablets.

Do not take a missed dose unless it is more than 6 hours until next scheduled dose.

If vomiting occurs after RETEVMO administration, do not take an additional dose and continue to the next scheduled time for the next dose.

2.4 Dosage Modifications for Concomitant Use of Acid-Reducing Agents
Avoid concomitant use of a PPI, a histamine-2 (H2) receptor antagonist, or a locally-acting antacid with RETEVMO [see Drug Interactions (7.1)]. If concomitant use cannot be avoided:

- Take RETEVMO with food when coadministered with a PPI.
- Take RETEVMO 2 hours before or 10 hours after administration of an H2 receptor antagonist.
- Take RETEVMO 2 hours before or 2 hours after administration of a locally-acting antacid.

2.5 Dosage Modifications for Adverse Reactions
The recommended dose reductions for adverse reactions are provided in Table 1.

<table>
<thead>
<tr>
<th>Dose Reduction</th>
<th>Patients Weighing Less Than 50 kg</th>
<th>Patients Weighing 50 kg or Greater</th>
</tr>
</thead>
<tbody>
<tr>
<td>First</td>
<td>80 mg orally twice daily</td>
<td>120 mg orally twice daily</td>
</tr>
<tr>
<td>Second</td>
<td>40 mg orally twice daily</td>
<td>80 mg orally twice daily</td>
</tr>
<tr>
<td>Third</td>
<td>40 mg orally once daily</td>
<td>40 mg orally twice daily</td>
</tr>
</tbody>
</table>

Permanently discontinue RETEVMO in patients unable to tolerate three dose reductions.

The recommended dosage modifications for adverse reactions are provided in Table 2.
## Table 2: Recommended RETEVMO Dosage Modifications for Adverse Reactions

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Severity</th>
<th>Dosage Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatotoxicity [see Warnings and Precautions (5.1)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO and monitor AST/ALT once weekly until resolution to Grade 1 or baseline.</td>
</tr>
<tr>
<td></td>
<td>or Grade 4</td>
<td>• Resume at reduced dose by 2 dose levels and monitor AST and ALT once weekly until 4 weeks after reaching dose taken prior to the onset of Grade 3 or 4 increased AST or ALT.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increase dose by 1 dose level after a minimum of 2 weeks without recurrence and then increase to dose taken prior to the onset of Grade 3 or 4 increased AST or ALT after a minimum of 4 weeks without recurrence.</td>
</tr>
<tr>
<td>Interstitial Lung Disease/ Pneumonitis [see Warnings and Precautions (5.2)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO until resolution.</td>
</tr>
<tr>
<td></td>
<td>or Grade 4</td>
<td>• Resume at a reduced dose.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Discontinue RETEVMO for recurrent ILD/pneumonitis.</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>• Discontinue RETEVMO for confirmed ILD/pneumonitis.</td>
</tr>
<tr>
<td>Hypertension [see Warnings and Precautions (5.3)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Discontinue RETEVMO.</td>
</tr>
<tr>
<td>QT Interval Prolongation [see Warnings and Precautions (5.4)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO until recovery to baseline or Grade 0 or 1.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Resume at a reduced dose.</td>
</tr>
<tr>
<td>Hemorrhagic Events [see Warnings and Precautions (5.5)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO until recovery to baseline or Grade 0 or 1.</td>
</tr>
<tr>
<td></td>
<td>or Grade 4</td>
<td>• Discontinue RETEVMO for severe or life-threatening hemorrhagic events.</td>
</tr>
<tr>
<td>Hypersensitivity Reactions [see Warnings and Precautions (5.6)]</td>
<td>All Grades</td>
<td>• Withhold RETEVMO until resolution of the event. Initiate corticosteroids.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Resume at a reduced dose by 3 dose levels while continuing corticosteroids.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increase dose by 1 dose level each week until the dose taken prior to the onset of hypersensitivity is reached, then taper corticosteroids.</td>
</tr>
<tr>
<td>Hypothyroidism [see Warnings and Precautions (5.9)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO until resolution to Grade 1 or baseline.</td>
</tr>
<tr>
<td></td>
<td>or Grade 4</td>
<td>• Discontinue RETEVMO based on severity.</td>
</tr>
<tr>
<td>Other Adverse Reactions [see Adverse Reactions (6.1)]</td>
<td>Grade 3</td>
<td>• Withhold RETEVMO until recovery to baseline or Grade 0 or 1.</td>
</tr>
<tr>
<td></td>
<td>or Grade 4</td>
<td>• Resume at a reduced dose.</td>
</tr>
</tbody>
</table>

### 2.6 Dosage Modifications for Concomitant Use of Strong and Moderate CYP3A Inhibitors

Avoid concomitant use of strong and moderate CYP3A inhibitors with RETEVMO. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the RETEVMO dose as recommended in Table 3. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume RETEVMO at the dose taken prior to initiating the CYP3A inhibitor [see Drug Interactions (7.1)].

## Table 3: Recommended RETEVMO Dosage for Concomitant Use of Strong and Moderate CYP3A Inhibitors

<table>
<thead>
<tr>
<th>Current RETEVMO Dosage</th>
<th>Recommended RETEVMO Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>120 mg orally twice daily</td>
<td>Moderate CYP3A Inhibitor: 80 mg orally twice daily, Strong CYP3A Inhibitor: 40 mg orally twice daily</td>
</tr>
<tr>
<td>160 mg orally twice daily</td>
<td>Moderate CYP3A Inhibitor: 120 mg orally twice daily, Strong CYP3A Inhibitor: 80 mg orally twice daily</td>
</tr>
</tbody>
</table>
2.7 Dosage Modification for Severe Hepatic Impairment

Reduce the recommended dosage of RETEVMO for patients with severe hepatic impairment as recommended in Table 4 [see Use in Specific Populations (8.7)].

Table 4: Recommended RETEVMO Dosage for Severe Hepatic Impairment

<table>
<thead>
<tr>
<th>Current RETEVMO Dosage</th>
<th>Recommended RETEVMO Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>120 mg orally twice daily</td>
<td>80 mg orally twice daily</td>
</tr>
<tr>
<td>160 mg orally twice daily</td>
<td>80 mg orally twice daily</td>
</tr>
</tbody>
</table>

3 DOSAGE FORMS AND STRENGTHS

Capsules:
- 40 mg: gray opaque capsule imprinted with "Lilly", “3977” and “40 mg” in black ink.
- 80 mg: blue opaque capsule imprinted with "Lilly", “2980” and “80 mg” in black ink.

Tablets:
- 40 mg: light gray, film coated, round tablet debossed with “Ret 40” on one side and “5340” on the other side.
- 80 mg: dark red-purple, film coated, round tablet debossed with “Ret 80” on one side and “6082” on the other side.
- 120 mg: light purple, film coated, round tablet debossed with “Ret 120” on one side and “6120” on the other side.
- 160 mg: light pink, film coated, round tablet debossed with “Ret 160” on one side and “5562” on the other side.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Hepatotoxicity

Serious hepatic adverse reactions occurred in 3% of patients treated with RETEVMO. Increased AST occurred in 59% of patients, including Grade 3 or 4 events in 11% and increased ALT occurred in 55% of patients, including Grade 3 or 4 events in 12% [see Adverse Reactions (6.1)]. The median time to first onset for increased AST was 6 weeks (range: 1 day to 3.4 years) and increased ALT was 5.8 weeks (range: 1 day to 2.5 years).

Monitor ALT and AST prior to initiating RETEVMO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose or permanently discontinue RETEVMO based on the severity [see Dosage and Administration (2.5)].

5.2 Interstitial Lung Disease/Pneumonitis

Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with RETEVMO. ILD/pneumonitis occurred in 1.8% of patients who received RETEVMO, including 0.3% with Grade 3 or 4 events, and 0.3% with fatal reactions.

Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold RETEVMO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue RETEVMO based on severity of confirmed ILD [see Dosage and Administration (2.5)].

5.3 Hypertension

Hypertension occurred in 41% of patients, including Grade 3 hypertension in 20% and Grade 4 in one (0.1%) patient [see Adverse Reactions (6.1)]. Overall, 6.3% had their dose interrupted and 1.3% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications.

Do not initiate RETEVMO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating RETEVMO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. Initiate or adjust
anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue RETEVMO based on the severity [see Dosage and Administration (2.5)].

5.4 QT Interval Prolongation

RETEVMO can cause concentration-dependent QT interval prolongation [see Clinical Pharmacology (12.2)]. An increase in QTcF interval to >500 ms was measured in 7% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 20% of patients [see Adverse Reactions (6.1)]. RETEVMO has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction.

Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Assess QT interval, electrolytes and TSH at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea. Correct hypokalemia, hypomagnesemia and hypocalcemia prior to initiating RETEVMO and during treatment.

Monitor the QT interval more frequently when RETEVMO is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and dose reduce or permanently discontinue RETEVMO based on the severity [see Dosage and Administration (2.5)].

5.5 Hemorrhagic Events

Serious including fatal hemorrhagic events can occur with RETEVMO. Grade ≥3 hemorrhagic events occurred in 3.1% of patients treated with RETEVMO, including 4 (0.5%) patients with fatal hemorrhagic events, including cerebral hemorrhage (n = 2), tracheostomy site hemorrhage (n = 1), and hemoptysis (n=1).

Permanently discontinue RETEVMO in patients with severe or life-threatening hemorrhage [see Dosage and Administration (2.5)].

5.6 Hypersensitivity

Hypersensitivity occurred in 6% of patients receiving RETEVMO, including Grade 3 hypersensitivity in 1.9%. The median time to onset was 1.9 weeks (range: 5 days to 2 years). Signs and symptoms of hypersensitivity included fever, rash and arthralgias or myalgias with concurrent decreased platelets or transaminitis.

If hypersensitivity occurs, withhold RETEVMO and begin corticosteroids at a dose of 1 mg/kg prednisone (or equivalent). Upon resolution of the event, resume RETEVMO at a reduced dose and increase the dose of RETEVMO by 1 dose level each week as tolerated until reaching the dose taken prior to onset of hypersensitivity [see Dosage and Administration (2.5)]. Continue steroids until patient reaches target dose and then taper. Permanently discontinue RETEVMO for recurrent hypersensitivity.

5.7 Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) occurred in 0.6% of patients with medullary thyroid carcinoma receiving RETEVMO [see Adverse Reactions (6.1)]. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.

5.8 Risk of Impaired Wound Healing

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, RETEVMO has the potential to adversely affect wound healing.

Withhold RETEVMO for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of RETEVMO after resolution of wound healing complications has not been established.

5.9 Hypothyroidism

RETEVMO can cause hypothyroidism. Hypothyroidism occurred in 13% of patients treated with RETEVMO; all reactions were Grade 1 or 2. Hypothyroidism occurred in 13% of patients (50/373) with thyroid cancer and 13% of patients (53/423) with other solid tumors including NSCLC [see Adverse Reactions (6.1)].

Monitor thyroid function before treatment with RETEVMO and periodically during treatment. Treat with thyroid hormone replacement as clinically indicated. Withhold RETEVMO until clinically stable or permanently discontinue RETEVMO based on severity [see Dosage and Administration (2.5)].
5.10 Embryo-Fetal Toxicity

Based on data from animal reproduction studies and its mechanism of action, RETEVMO can cause fetal harm when administered to a pregnant woman. Administration of selpercatinib to pregnant rats during organogenesis at maternal exposures that were approximately equal to those observed at the recommended human dose of 160 mg twice daily resulted in embryolethality and malformations.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RETEVMO and for 1 week after the last dose.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Hepatotoxicity [see Warnings and Precautions (5.1)]
- Interstitial Lung Disease / Pneumonitis [see Warnings and Precautions (5.2)]
- Hypertension [see Warnings and Precautions (5.3)]
- QT Interval Prolongation [see Warnings and Precautions (5.4)]
- Hemorrhagic Events [see Warnings and Precautions (5.5)]
- Hypersensitivity Events [see Warnings and Precautions (5.6)]
- Tumor Lysis Syndrome [see Warnings and Precautions (5.7)]
- Risk of Impaired Wound Healing [see Warnings and Precautions (5.8)]
- Hypothyroidism [see Warnings and Precautions (5.9)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

**RET Gene Fusion or Gene Mutation Positive Solid Tumors**

The pooled safety population described in the WARNINGS and PRECAUTIONS and below reflects exposure to RETEVMO as a single agent at 160 mg orally twice daily evaluated in 796 patients with advanced solid tumors in LIBRETTO-001 [see Clinical Studies (14)]. Among the 796 patients who received RETEVMO, 84% were exposed for 6 months or longer and 73% were exposed for greater than one year. Among these patients, 96% received at least one dose of RETEVMO at the recommended dosage of 160 mg orally twice daily.

The median age was 59 years (range: 15 to 92 years); 0.3% were pediatric patients 12 to 16 years of age; 51% were male; and 69% were White, 23% were Asian, 5% were Hispanic/Latino, and 3% were Black. The most common tumors were NSCLC (45%), MTC (40%), and non-medullary thyroid carcinoma (7%).

Serious adverse reactions occurred in 44% of patients who received RETEVMO. The most frequent serious adverse reactions (≥2% of patients) were pneumonia, pleural effusion, abdominal pain, hemorrhage, hypersensitivity, dyspnea, and hyponatremia. Fatal adverse reactions occurred in 3% of patients; fatal adverse reactions included sepsis (n = 6), respiratory failure (n = 5), hemorrhage (n = 4), pneumonia (n = 3), pneumonitis (n = 2), cardiac arrest (n=2), sudden death (n = 1), and cardiac failure (n = 1).

Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received RETEVMO. Adverse reactions resulting in permanent discontinuation in ≥0.5% of patients included increased ALT (0.6%), fatigue (0.6%), sepsis (0.5%), and increased AST (0.5%).

Dose interruptions due to an adverse reaction occurred in 64% of patients who received RETEVMO. Adverse reactions requiring dosage interruption in ≥5% of patients included increased ALT, increased AST, diarrhea, and hypertension.

Dose reductions due to an adverse reaction occurred in 41% of patients who received RETEVMO. Adverse reactions requiring dosage reductions in ≥2% of patients included increased ALT, increased AST, QT prolongation, fatigue, diarrhea, drug hypersensitivity, and edema.

The most common adverse reactions (≥25%) were edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache.

The most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), decreased sodium, and decreased calcium.
Table 5 summarizes the adverse reactions in LIBRETTO-001.

Table 5: Adverse Reactions (≥20%) in Patients Who Received RETEVMO in LIBRETTO-001

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>RETEVMO (n = 796)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4 (%)</td>
<td>Grades 3-4 (%)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea¹</td>
<td>47</td>
<td>5*</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>43</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain²</td>
<td>34</td>
<td>2.5*</td>
</tr>
<tr>
<td>Constipation</td>
<td>33</td>
<td>0.8*</td>
</tr>
<tr>
<td>Nausea</td>
<td>31</td>
<td>1.1*</td>
</tr>
<tr>
<td>Vomiting</td>
<td>22</td>
<td>1.8*</td>
</tr>
<tr>
<td>Vascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>41</td>
<td>20</td>
</tr>
<tr>
<td>General</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edema³</td>
<td>49</td>
<td>0.8*</td>
</tr>
<tr>
<td>Fatigue⁴</td>
<td>46</td>
<td>3.1*</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>21</td>
<td>0.3*</td>
</tr>
<tr>
<td>Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash⁵</td>
<td>33</td>
<td>0.6*</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache⁶</td>
<td>28</td>
<td>1.4*</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough⁷</td>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>Dyspnea⁸</td>
<td>22</td>
<td>3.1</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolonged QT interval</td>
<td>21</td>
<td>4.8*</td>
</tr>
<tr>
<td>Blood and Lymphatic System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemorrhage⁹</td>
<td>22</td>
<td>2.6</td>
</tr>
</tbody>
</table>

¹ Diarrhea includes diarrhea, defecation urgency, frequent bowel movements, gastrointestinal hypermotility, anal incontinence.
² Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, abdominal tenderness, epigastric discomfort, gastrointestinal pain.
³ Edema includes edema, edema peripheral, face edema, periorbital edema, eye edema, eyelid edema, orbital edema, localized edema, lymphedema, scrotal edema, peripheral swelling, scrotal swelling, swelling, swelling face, eye swelling, generalized edema, genital edema.
⁴ Fatigue includes fatigue, asthenia, malaise.
⁵ Rash includes rash, rash erythematous, rash macular, rash maculopapular, rash morbilliform, rash papular, rash pruritic, butterfly rash, exfoliative rash, rash follicular, rash generalized, rash vesicular.
⁶ Headache includes headache, sinus headache, tension headache.
⁷ Includes cough, productive cough, upper airway cough syndrome.
⁸ Includes dyspnea, dyspnea exertional, dyspnea at rest.
⁹ Hemorrhage includes hemorrhage, epistaxis, hematuria, hemoptysis, contusion, rectal hemorrhage, vaginal hemorrhage, ecchymosis, hematoma, hemorrhage, anal hemorrhage, blood blister, blood urine present, cerebral hemorrhage, gastric hemorrhage, hemorrhage intracranial, hemorrhage subcutaneous, spontaneous hematoma, abdominal wall hematoma, angina bullosa hemorrhagica, conjunctival hemorrhage, disseminated intravascular coagulation, diverticulum intestinal hemorrhagic, eye hemorrhage, gastrointestinal hemorrhage, gingival bleeding, hematemesis, hemorrhagic stroke.
hemorrhoidal hemorrhage, hepatic hemorrhage, hepatic hematoma, intraabdominal hemorrhage, laryngeal hemorrhage, lower gastrointestinal hemorrhage, melena, mouth hemorrhage, occult blood positive, post procedural hemorrhage, postmenopausal hemorrhage, pelvic hematoma, periorbital hematoma, periorbital hemorrhage, pharyngeal hemorrhage, pulmonary contusion, purpura, retinal hemorrhage, retroperitoneal hematoma, scleral hemorrhage, skin hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, upper gastrointestinal hemorrhage, uterine hemorrhage, vessel puncture site hematoma.

* Only includes a grade 3 adverse reaction.

Clinically relevant adverse reactions in ≤15% of patients who received RETEVMO include hypothyroidism (13%); hypersensitivity (6%); interstitial lung disease/pneumonitis, chylothorax, chylous ascites or tumor lysis syndrome (all < 2%).

Table 6 summarizes the laboratory abnormalities in LIBRETTO-001.

### Table 6: Select Laboratory Abnormalities (≥20%) Worsening from Baseline in Patients Who Received RETEVMO in LIBRETTO-001

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>RETEVMO&lt;sup&gt;1&lt;/sup&gt;</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4&lt;sup&gt;#&lt;/sup&gt; (%)</td>
<td>Grades 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased AST</td>
<td>59</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Decreased calcium</td>
<td>59</td>
<td>5.7</td>
<td></td>
</tr>
<tr>
<td>Increased ALT</td>
<td>56</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Decreased albumin</td>
<td>56</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>Increased glucose</td>
<td>53</td>
<td>2.8</td>
<td></td>
</tr>
<tr>
<td>Increased creatinine</td>
<td>47</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>Decreased sodium</td>
<td>42</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Increased alkaline phosphatase</td>
<td>40</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td>Increased total cholesterol</td>
<td>35</td>
<td>1.7</td>
<td></td>
</tr>
<tr>
<td>Increased potassium</td>
<td>34</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Decreased glucose</td>
<td>34</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Decreased magnesium</td>
<td>33</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Increased bilirubin</td>
<td>30</td>
<td>2.8</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased lymphocytes</td>
<td>52</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Decreased platelets</td>
<td>37</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Decreased hemoglobin</td>
<td>28</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td>Decreased neutrophils</td>
<td>25</td>
<td>3.2</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 765 to 791 patients.

<sup>#</sup> Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03

Increased Creatinine

In healthy subjects administered RETEVMO 160 mg orally twice daily, serum creatinine increased 18% after 10 days. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed [see Clinical Pharmacology (12.3)].
7  DRUG INTERACTIONS

7.1  Effects of Other Drugs on RETEVMO

Acid-Reducing Agents
Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce RETEVMO anti-tumor activity.

Avoid concomitant use of PPIs, H2 receptor antagonists, and locally-acting antacids with RETEVMO. If coadministration cannot be avoided, take RETEVMO with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally-acting antacid) [see Dosage and Administration (2.4)].

Strong and Moderate CYP3A Inhibitors
Concomitant use of RETEVMO with a strong or moderate CYP3A inhibitor increases selpercatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of RETEVMO adverse reactions, including QTc interval prolongation.

Avoid concomitant use of strong and moderate CYP3A inhibitors with RETEVMO. If concomitant use of strong and moderate CYP3A inhibitors cannot be avoided, reduce the RETEVMO dosage and monitor the QT interval with ECGs more frequently [see Dosage and Administration (2.6), Warning and Precautions (5.4)].

Strong and Moderate CYP3A Inducers
Concomitant use of RETEVMO with a strong or moderate CYP3A inducer decreases selpercatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce RETEVMO anti-tumor activity.

Avoid coadministration of strong or moderate CYP3A inducers with RETEVMO.

7.2  Effects of RETEVMO on Other Drugs

CYP2C8 and CYP3A Substrates
RETEVMO is a moderate CYP2C8 inhibitor and a weak CYP3A inhibitor. Concomitant use of RETEVMO with CYP2C8 and CYP3A substrates increases their plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of RETEVMO with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

 Certain P-gp Substrates
RETEVMO is a P-gp inhibitor. Concomitant use of RETEVMO with P-gp substrates increases their plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of RETEVMO with P-gp substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp substrates provided in their approved product labeling.

7.3  Drugs that Prolong QT Interval

RETEVMO is associated with QTc interval prolongation [see Warnings and Precautions (5.4), Clinical Pharmacology (12.2)]. Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.

8  USE IN SPECIFIC POPULATIONS

8.1  Pregnancy

Risk Summary
Based on findings from animal studies, and its mechanism of action [see Clinical Pharmacology (12.1)], RETEVMO can cause fetal harm when administered to a pregnant woman. There are no available data on RETEVMO use in pregnant women to inform drug-associated risk. Administration of selpercatinib to pregnant rats during the period of organogenesis resulted in embryolethality and malformations at maternal exposures that were approximately equal to the human exposure at the clinical dose of 160 mg twice daily. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data

Animal Data

Selpercatinib administration to pregnant rats during the period of organogenesis at oral doses ≥100 mg/kg [approximately 3.6 times the human exposure based on the area under the curve (AUC) at the clinical dose of 160 mg twice daily] resulted in 100% post-implantation loss. At the dose of 50 mg/kg [approximately equal to the human exposure (AUC) at the clinical dose of 160 mg twice daily], 6 of 8 females had 100% early resorptions; the remaining 2 females had high levels of early resorptions with only 3 viable fetuses across the 2 litters. All viable fetuses had decreased fetal body weight and malformations (2 with short tail and one with small snout and localized edema of the neck and thorax).

8.2 Lactation

Risk Summary

There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with RETEVMO and for 1 week after the last dose.

8.3 Females and Males of Reproductive Potential

Based on animal data, RETEVMO can cause embryolethality and malformations at doses resulting in exposures less than or equal to the human exposure at the clinical dose of 160 mg twice daily [see Use in Specific Populations (8.1)].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating RETEVMO [see Use in Specific Populations (8.1)].

Contraception

Females

Advise female patients of reproductive potential to use effective contraception during treatment with RETEVMO and for 1 week after the last dose.

Males

Advise males with female partners of reproductive potential to use effective contraception during treatment with RETEVMO and for 1 week after the last dose.

Infertility

RETENVMO may impair fertility in females and males of reproductive potential [see Use in Specific Populations (8.4), Nonclinical Toxicology (13.1)].

8.4 Pediatric Use

The safety and effectiveness of RETEVMO have been established in pediatric patients aged 12 years and older for medullary thyroid cancer (MTC) who require systemic therapy and for advanced RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). Use of RETEVMO for these indications is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients aged 12 years and older [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.2, 14.3)]. The safety and effectiveness of RETEVMO have not been established in these indications in patients less than 12 years of age.

The safety and effectiveness of RETEVMO have not been established in pediatric patients for other indications [see Indications and Usage (1)].

Juvenile Animal Toxicity Data

In a juvenile rat toxicity study, animals were dosed daily with selpercatinib from post-natal day 21 to day 70 (approximately equivalent to a human child to late adolescent). Selpercatinib increased physeal thickness of multiple bones, extending into the metaphysis and associated with decreased trabecular bone, which was not reversible at doses approximately equivalent to or greater than the adult human exposure at the clinical dose of 160 mg twice daily. Growth plate changes were associated with impairment of bone modeling, resulting in decreased femur length and with reduction in bone mineral density. Selpercatinib also induced reversible hypocellularity of bone marrow in males at ≥30 mg/kg (approximately equivalent to or greater than the adult human exposure at the clinical dose of 160 mg twice daily), and reversible alterations of dentin composition at ≥50 mg/kg (approximately 3 times the adult human exposure at the clinical dose of 160 mg twice daily). Irreversible, dose-dependent degeneration of testicular germinal epithelium, with vacuolation of Sertoli cells and corresponding depletion of spermatids in the epididymides, was also observed at ≥ 30 mg/kg.
Monitor growth plates in adolescent patients with open growth plates. Consider interrupting or discontinuing therapy based on the severity of any growth plate abnormalities and based on an individual risk-benefit assessment.

8.5 Geriatric Use
Of 796 patients who received RETEVMO, 34% (268 patients) were ≥65 years of age and 9% (74 patients) were ≥75 years of age. No overall differences were observed in the safety or effectiveness of RETEVMO between patients who were ≥65 years of age and younger patients.

8.6 Renal Impairment
No dosage modification is recommended for patients with mild to severe renal impairment [estimated Glomerular Filtration Rate (eGFR) ≥15 to 89 mL/min, estimated by Modification of Diet in Renal Disease (MDRD) equation]. The recommended dosage has not been established for patients with end-stage renal disease (ESRD) [see Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment
Reduce the dose when administering RETEVMO to patients with severe [total bilirubin greater than 3 to 10 times upper limit of normal (ULN) and any AST] hepatic impairment [see Dosage and Administration (2.7)]. No dosage modification is recommended for patients with mild (total bilirubin less than or equal to ULN with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST) or moderate (total bilirubin greater than 1.5 to 3 times ULN and any AST) hepatic impairment. Monitor for RETEVMO-related adverse reactions in patients with hepatic impairment [see Clinical Pharmacology (12.3)].

11 DESCRIPTION
RETEVMO contains selpercatinib, a kinase inhibitor. The molecular formula for selpercatinib is C\textsubscript{29}H\textsubscript{31}N\textsubscript{7}O\textsubscript{3} and the molecular weight is 525.61 g/mol. The chemical name is 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-methoxy-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile. Selpercatinib has the following chemical structure:

![Chemical Structure of Selpercatinib]

Selpercatinib is a white to light yellow powder that is slightly hygroscopic. The aqueous solubility of selpercatinib is pH dependent, from sparingly soluble at low pH to practically insoluble at neutral pH.

RETEVMO capsules contain either 40 mg or 80 mg of selpercatinib in hard gelatin capsules for oral use. Each capsule contains inactive ingredients of colloidal silicon dioxide and microcrystalline cellulose. The 40 mg capsule shell is composed of gelatin, titanium dioxide, ferric oxide black and black ink. The 80 mg capsule shell is composed of gelatin, titanium dioxide, FD&C blue #1 and black ink. The black ink is composed of shellac, potassium hydroxide and ferric oxide black.

RETEVMO tablets contain 40 mg, 80 mg, 120 mg or 160 mg of selpercatinib as film coated, debossed tablets for oral use. Each tablet contains inactive ingredients of croscarmellose sodium, hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. The tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Additionally, the film coating of the 40 mg, 80 mg, and 120 mg tablets contains ferrosferric oxide and the film coating of the 80 mg, 120 mg, and 160 mg tablets contain ferrosoferric oxide.
12.1 Mechanism of Action
Selpercatinib is a kinase inhibitor. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC\(_{50}\) values ranging from 0.92 nM to 67.8 nM. In other enzyme assays, selpercatinib also inhibited FGFR 1, 2, and 3 at higher concentrations that were still clinically achievable. In cellular assays, selpercatinib inhibited RET at approximately 60-fold lower concentrations than FGFR1 and 2 and approximately 8-fold lower concentration than VEGFR3.

Certain point mutations in RET or chromosomal rearrangements involving in-frame fusions of RET with various partners can result in constitutively activated chimeric RET fusion proteins that can act as oncogenic drivers by promoting cell proliferation of tumor cell lines. In viro and in vivo tumor models, selpercatinib demonstrated anti-tumor activity in cells harboring constitutive activation of RET proteins resulting from gene fusions and mutations, including CCDC6-RET, KIF5B-RET, RET V804M, and RET M918T. In addition, selpercatinib showed anti-tumor activity in mice intracranially implanted with a patient-derived RET fusion positive tumor.

12.2 Pharmacodynamics
Exposure-Response Relationship
Selpercatinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.

Cardiac Electrophysiology
The effect of RETEVMO on the QTc interval was evaluated in a thorough QT study in healthy subjects. The largest mean increase in QTc is predicted to be 10.6 msec (upper 90% confidence interval: 12.1 msec) at the mean steady-state maximum concentration (C\(_{\text{max}}\)) observed in patients after administration of 160 mg twice daily. The increase in QTc was concentration-dependent.

12.3 Pharmacokinetics
The pharmacokinetics of selpercatinib capsules were evaluated in patients with locally advanced or metastatic solid tumors administered 160 mg twice daily unless otherwise specified. The capsule and tablet dosage forms of selpercatinib are bioequivalent. Steady state selpercatinib AUC and C\(_{\text{max}}\) increased in a slightly greater than dose proportional manner over the dose range of 20 mg once daily to 240 mg twice daily [0.06 to 1.5 times the maximum recommended total daily dosage].

Steady-state was reached by approximately 7 days and the median accumulation ratio after administration of 160 mg twice daily was 3.4-fold. Mean steady-state selpercatinib [coefficient of variation (CV%)] C\(_{\text{max}}\) was 2,980 (53%) ng/mL and AUC\(_{0-24h}\) was 51,600 (58%) ng*h/mL.

Absorption
The median t\(_{\text{max}}\) of selpercatinib is 2 hours. The mean absolute bioavailability of RETEVMO capsules is 73% (60% to 82%) in healthy subjects.

Effect of Food
For both the capsule and tablet dosage forms no clinically significant differences in selpercatinib AUC or C\(_{\text{max}}\) were observed following administration of a high-fat meal (approximately 900 calories, 58 grams carbohydrate, 56 grams fat and 43 grams protein) in healthy subjects.

Distribution
The apparent volume of distribution (V\(_{\text{app}}/\text{F}\)) of selpercatinib is 191 L.

Protein binding of selpercatinib is 96% in vitro and is independent of concentration. The blood-to-plasma concentration ratio is 0.7.

Elimination
The apparent clearance (CL/F) of selpercatinib is 6 L/h in patients and the half-life is 32 hours following oral administration of RETEVMO in healthy subjects.

Metabolism
Selpercatinib is metabolized predominantly by CYP3A4. Following oral administration of a single radiolabeled 160 mg dose of selpercatinib to healthy subjects, unchanged selpercatinib constituted 86% of the radioactive drug components in plasma.

Excretion
Following oral administration of a single radiolabeled 160 mg dose of selpercatinib to healthy subjects, 69% of the administered dose was recovered in feces (14% unchanged) and 24% in urine (12% unchanged).

**Specific Populations**

The apparent volume of distribution and clearance of selpercatinib increase with increasing body weight (27 kg to 179 kg).

No clinically significant differences in the pharmacokinetics of selpercatinib were observed based on age (15 years to 92 years), sex, or mild, moderate, or severe renal impairment (eGFR ≥ 15 to 89 mL/min). The effect of ESRD on selpercatinib pharmacokinetics has not been studied.

**Patients with Hepatic Impairment**

The selpercatinib AUC\(_{0-\text{INF}}\) increased by 7%, 32%, and 77% in subjects with mild (total bilirubin less than or equal to ULN with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST), moderate (total bilirubin greater than 1.5 to 3 times ULN and any AST), and severe (total bilirubin greater than 3 to 10 times ULN and any AST) hepatic impairment, respectively, compared to subjects with normal hepatic function.

**Drug Interaction Studies**

**Clinical Studies and Model-Informed Approaches**

**Proton-Pump Inhibitors (PPI):** Coadministration with multiple daily doses of omeprazole (PPI) decreased selpercatinib AUC\(_{0-\text{INF}}\) and C\(_{\text{max}}\) when RETEVMO was administered fasting. Coadministration with multiple daily doses of omeprazole did not significantly change the selpercatinib AUC\(_{0-\text{INF}}\) and C\(_{\text{max}}\) when RETEVMO was administered with food (Table 7).

**Table 7: Change in Selpercatinib Exposure After Coadministration with PPI**

<table>
<thead>
<tr>
<th></th>
<th>Selpercatinib AUC(_{0-\text{INF}})</th>
<th>Selpercatinib C(_{\text{max}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>RETEVMO fasting</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>RETEVMO fasting + PPI</td>
<td>↓ 69%</td>
<td>↓ 88%</td>
</tr>
<tr>
<td>RETEVMO with a high-fat meal(^1) + PPI</td>
<td>↑ 2%</td>
<td>↓ 49%</td>
</tr>
<tr>
<td>RETEVMO with a low-fat meal(^2) + PPI</td>
<td>No change</td>
<td>↓ 22%</td>
</tr>
</tbody>
</table>

\(^1\) High-fat meal: approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively; approximately 800 to 1,000 calories total.

\(^2\) Low-fat meal: approximately 390 calories and 10 g of fat.

**H\(_2\) Receptor Antagonists:** No clinically significant differences in selpercatinib pharmacokinetics were observed when coadministered with multiple daily doses of ranitidine (H\(_2\) receptor antagonist) given 10 hours prior to and 2 hours after the RETEVMO dose (administered fasting).

**Strong CYP3A Inhibitors:** Coadministration of multiple doses of itraconazole (strong CYP3A inhibitor) increased the selpercatinib AUC\(_{0-\text{INF}}\) by 133% and C\(_{\text{max}}\) by 30%.

**Moderate CYP3A Inhibitors:** Coadministration of multiple doses of diltiazem, fluconazole, or verapamil (moderate CYP3A inhibitors) is predicted to increase the selpercatinib AUC by 60-99% and C\(_{\text{max}}\) by 46-76%.

**Strong CYP3A Inducers:** Coadministration of multiple doses of rifampin (strong CYP3A inducer) decreased the selpercatinib AUC\(_{0-\text{INF}}\) by 87% and C\(_{\text{max}}\) by 70%.

**Moderate CYP3A Inducers:** Coadministration of multiple doses of bosentan or efavirenz (moderate CYP3A inducers) is predicted to decrease the selpercatinib AUC by 40-70% and C\(_{\text{max}}\) by 34-57%.

**Weak CYP3A Inducers:** Coadministration of multiple doses of modafinil (weak CYP3A inducer) is predicted to decrease the selpercatinib AUC by 33% and C\(_{\text{max}}\) by 26%.

**CYP2C8 Substrates:** Coadministration of RETEVMO with repaglinide (sensitive CYP2C8 substrate) increased the repaglinide AUC\(_{0-\text{INF}}\) by 188% and C\(_{\text{max}}\) by 91%.

**CYP3A Substrates:** Coadministration of RETEVMO with midazolam (sensitive CYP3A substrate) increased the midazolam AUC\(_{0-\text{INF}}\) by 54% and C\(_{\text{max}}\) by 39%.

**P-glycoprotein (P-gp) Substrates:** Coadministration of RETEVMO with dabigatran (P-gp substrate) increased the dabigatran AUC\(_{0-\text{INF}}\) by 38% and C\(_{\text{max}}\) by 43%.
**P-gp Inhibitors:** No clinically significant differences in selpercatinib pharmacokinetics were observed when coadministered with a single dose of rifampin (P-gp inhibitor).

**MATE1 Substrates:** No clinically significant differences in glucose levels were observed when metformin (MATE1 substrate) was coadministered with selpercatinib.

**In Vitro Studies**

**CYP Enzymes:** Selpercatinib does not inhibit or induce CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations.

**Transporter Systems:** Selpercatinib inhibits MATE1 and BCRP, but does not inhibit OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BSEP, and MATE2-K at clinically relevant concentrations. Selpercatinib may increase serum creatinine by decreasing renal tubular secretion of creatinine via inhibition of MATE1 [see Adverse Effects (6.1)]. Selpercatinib is a substrate for P-gp and BCRP, but not for OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K.

**13 NONCLINICAL TOXICOLOGY**

**13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Carcinogenicity studies have not been conducted with selpercatinib. Selpercatinib was not mutagenic in the in vitro bacterial reverse mutation (Ames) assays, with or without metabolic activation, or clastogenic in the in vitro micronucleus assay in human peripheral lymphocytes, with or without metabolic activation. Selpercatinib was positive in the in vivo micronucleus assay in rats at concentrations >7 times the \( C_{\text{max}} \) at the human dose of 160 mg twice daily.

In general toxicology studies, male rats and minipigs exhibited testicular degeneration which was associated with luminal cell debris and/or reduced luminal sperm in the epididymis at selpercatinib exposures approximately 0.4 (rat) and 0.1 (minipig) times the clinical exposure by AUC at the recommended human dose. In a dedicated fertility study in male rats, administration of selpercatinib at doses up to 30 mg/kg/day (approximately twice the clinical exposure by AUC at the 160 mg twice daily dose) for 28 days prior to cohabitation with untreated females did not affect mating or have clear effects on fertility. Males did, however, display a dose-dependent increase in testicular germ cell depletion and spermatid retention at doses ≥3 mg/kg (~0.2 times the clinical exposure by AUC at the 160 mg twice daily dose) accompanied by altered sperm morphology at 30 mg/kg.

In a dedicated fertility study in female rats treated with selpercatinib for 15 days before mating to Gestational Day 7, there were decreases in the number of estrous cycles at a dose of 75 mg/kg (approximately equal to the human exposure by AUC at the 160 mg twice daily clinical dose). While selpercatinib did not have clear effects on mating performance or ability to become pregnant at any dose level, half of females at the 75 mg/kg dose level had 100% nonviable embryos. At the same dose level in females with some viable embryos there were increases in post-implantation loss. In a 3-month general toxicology study in minipigs, there were findings of decreased or absent corpora lutea at a selpercatinib dose of 15 mg/kg (approximately 0.3 times the human exposure by AUC at the 160 mg twice daily clinical dose). Corpora luteal cysts were present in the minipig at selpercatinib doses ≥2 mg/kg (approximately 0.07 times the human exposure by AUC at the 160 mg twice daily clinical dose).

**14 CLINICAL STUDIES**

**14.1 RET Fusion-Positive Non-Small Cell Lung Cancer**

The efficacy of RETEVMO was evaluated in patients with advanced RET fusion-positive NSCLC enrolled in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001, NCT03157128). The study enrolled patients with advanced or metastatic RET fusion-positive NSCLC who had progressed on platinum-based chemotheraphy and patients with locally advanced (stage III) who were not candidates for surgical resection or definitive chemoradiation) or metastatic NSCLC without prior systemic therapy in separate cohorts. Identification of a RET gene alteration was prospectively determined in local laboratories using next generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) or other local testing methods. Adult patients received RETEVMO 160 mg orally twice daily until unacceptable toxicity or disease progression; patients enrolled in the dose escalation phase were permitted to adjust their dose to 160 mg twice daily. The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR), as determined by a blinded independent review committee (BIRC) according to RECIST v1.1.

**RET Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy**

Efficacy was evaluated in 247 patients with RET fusion-positive NSCLC previously treated with platinum chemotherapy enrolled into a cohort of LIBRETTO-001.
The median age was 61 years (range: 23 to 81); 57% were female; 44% were White, 48% were Asian, 4.9% were Black, and 2.8% were Hispanic/Latino. ECOG performance status was 0-1 (97%) or 2 (3%) and 97% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range 1–15); 58% had prior anti-PD-1/PD-L1 therapy. RET fusions were detected in 94% of patients using NGS (84.6% tumor samples; 9.3% blood or plasma samples), 4.0% using FISH, 1.6% using PCR and 0.4% by other local testing methods.

Efficacy results for previously treated RET fusion-positive NSCLC are summarized in Table 8.

**Table 8: Efficacy Results in LIBRETTO-001 (RET Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy)**

<table>
<thead>
<tr>
<th>RETEVMO (n = 247)</th>
<th>Overall Response Rate¹ (95% CI)</th>
<th>61% (55%, 67%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Complete response</td>
<td>7.3%</td>
</tr>
<tr>
<td></td>
<td>Partial response</td>
<td>54%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Response</th>
<th>Median in months (95% CI)</th>
<th>28.6 (20, NE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% with ≥ 12 months²</td>
<td></td>
<td>63%</td>
</tr>
</tbody>
</table>

¹ Confirmed overall response rate assessed by BIRC.
² Based on observed duration of response.

For the 144 patients who received an anti-PD-1 or anti-PD-L1 therapy, either sequentially or concurrently with platinum-based chemotherapy, an exploratory subgroup analysis of ORR was 63% (95% CI: 54%, 70%) and the median DOR was 28.6 months (95% CI: 14.8, NE).

Among the 247 patients with previously treated RET fusion-positive NSCLC, 16 had measurable CNS metastases at baseline as assessed by BIRC. One patient received radiation therapy (RT) to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 14 of these 16 patients; 39% of responders had an intracranial DOR of ≥ 12 months.

**Treatment-naïve RET Fusion-Positive NSCLC**

Efficacy was evaluated in 69 patients with treatment-naïve RET fusion-positive NSCLC enrolled into a cohort of LIBRETTO-001.

The median age was 63 years (range 23 to 92): 62% were female; 70% were White, 19% were Asian, and 6% were Black. ECOG performance status was 0-1 (94%) or 2 (6%) and 99% of patients had metastatic disease. RET fusions were detected in 91% of patients using NGS (60.9% tumor samples; 30.4% in blood), 7.2% using FISH and 1.4% using PCR.

Efficacy results for treatment naïve RET fusion-positive NSCLC are summarized in Table 9.

**Table 9: Efficacy Results in LIBRETTO-001 (Treatment-Naïve RET Fusion-Positive NSCLC)**

<table>
<thead>
<tr>
<th>RETEVMO (n = 69)</th>
<th>Overall Response Rate¹ (95% CI)</th>
<th>84% (73%, 92%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Complete response</td>
<td>5.8%</td>
</tr>
<tr>
<td></td>
<td>Partial response</td>
<td>78%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Response</th>
<th>Median in months (95% CI)</th>
<th>20.2 (13, NE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% with ≥ 12 months²</td>
<td></td>
<td>50%</td>
</tr>
</tbody>
</table>

¹ Confirmed overall response rate assessed by BIRC.
² Based on observed duration of response.

NE = not estimable
Among the 69 patients with treatment-naïve RET fusion-positive NSCLC, 5 had measurable CNS metastases at baseline as assessed by BIRC. Two patients received RT to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 4 of these 5 patients; 38% of responders had an intracranial DOR of ≥ 12 months.

14.2 RET-Mutant Medullary Thyroid Cancer

The efficacy of RETEVMO was evaluated in patients with RET-mutant MTC enrolled in a multicenter, open-label, multi-cohort clinical trial (LIBRETT0-001, NCT03157128). The study enrolled patients with advanced or metastatic RET-mutant MTC who had been previously treated with cabozantinib or vandetanib (or both) and patients with advanced or metastatic RET-mutant MTC who were naïve to cabozantinib and vandetanib in separate cohorts.

RET-Mutant MTC Previously Treated with Cabozantinib or Vandetanib

Efficacy was evaluated in 55 patients with RET-mutant advanced MTC who had previously treated with cabozantinib or vandetanib enrolled into a cohort of LIBRETT0-001. The median age was 57 years (range: 17 to 84); 66% were male; 89% were White, 7% were Hispanic/Latino, and 1.8% were Black. ECOG performance status was 0-1 (95%) or 2 (5%) and 98% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range 1 – 8). RET mutation status was detected in 82% of patients using NGS (78% tumor samples; 4% blood or plasma), 16% using PCR, and 2% using an unknown test. The protocol excluded patients with synonymous, frameshift or nonsense RET mutations; the specific mutations used to identify and enroll patients are described in Table 10.

<table>
<thead>
<tr>
<th>RET Mutation Type¹</th>
<th>Previously Treated (n = 55)</th>
<th>Cabozantinib/Vandetanib Naïve (n = 88)</th>
<th>Total (n = 143)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M918T</td>
<td>33</td>
<td>49</td>
<td>82</td>
</tr>
<tr>
<td>Extracellular cysteine mutation²</td>
<td>7</td>
<td>20</td>
<td>27</td>
</tr>
<tr>
<td>V804M or V804L</td>
<td>5⁴</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>Other³</td>
<td>10</td>
<td>13</td>
<td>23</td>
</tr>
</tbody>
</table>

¹ Somatic or germline mutations; protein change.
² Extracellular cysteine mutations involving cysteine residues 609, 611, 618, 620, 630, and 634.
⁴ One patient also had a M918T mutation.

Efficacy results for RET-mutant MTC are summarized in Table 11.

<table>
<thead>
<tr>
<th>Overall Response Rate¹ (95% CI)</th>
<th>RETEVMO (n = 55)</th>
<th>RETEVMO (n = 55)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>69% (55%, 81%)</td>
<td>69% (55%, 81%)</td>
</tr>
<tr>
<td>Partial response</td>
<td>9%</td>
<td>9%</td>
</tr>
<tr>
<td>% with ≥6 months²</td>
<td>60%</td>
<td>60%</td>
</tr>
</tbody>
</table>

¹ Confirmed overall response rate assessed by BIRC.
² Based on observed duration of response.

NE = not estimable
Cabozantinib and Vandetanib-naïve RET-Mutant MTC

Efficacy was evaluated in 88 patients with RET-mutant MTC who were cabozantinib and vandetanib treatment-naïve enrolled into a cohort of LIBRETTO-001.

The median age was 58 years (range: 15 to 82) with two patients (2.3%) aged 12 to 16 years; 66% were male; and 86% were White, 4.5% were Asian, and 2.3% were Hispanic/Latino. ECOG performance status was 0–1 (97%) or 2 (3.4%). All patients (100%) had metastatic disease and 18% had received 1 or 2 prior systemic therapies (including 8% kinase inhibitors, 4.5% chemotherapy, 2.3% anti-PD1/PD-L1 therapy, and 1.1% radioactive iodine). RET mutation status was detected in 77.3% of patients using NGS (75.0% tumor samples; 2.3% blood samples), 18.2% using PCR, and 4.5% using an unknown test. The mutations used to identify and enroll patients are described in Table 10.

Efficacy results for cabozantinib and vandetanib-naïve RET-mutant MTC are summarized in Table 12.

Table 12: Efficacy Results in LIBRETTO-001 (Cabozantinib and Vandetanib-naïve RET-Mutant MTC)

<table>
<thead>
<tr>
<th></th>
<th>RETEVMO (n = 88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Response Rate¹ (95% CI)</td>
<td>73% (62%, 82%)</td>
</tr>
<tr>
<td>Complete response</td>
<td>11%</td>
</tr>
<tr>
<td>Partial response</td>
<td>61%</td>
</tr>
</tbody>
</table>

Duration of Response

<table>
<thead>
<tr>
<th></th>
<th>22.0 (NE, NE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% with ≥6 months²</td>
<td>61%</td>
</tr>
</tbody>
</table>

¹ Confirmed overall response rate assessed by BIRC.
² Based on observed duration of response.
NE = not estimable

14.3 RET Fusion-Positive Thyroid Cancer

The efficacy of RETEVMO was evaluated in patients with advanced RET fusion-positive thyroid cancer enrolled in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001, NCT03157128). Efficacy was evaluated in 27 patients with RET fusion-positive thyroid cancer who were radioactive iodine (RAI)-refractory (if RAI was an appropriate treatment option) and were systemic therapy naïve and patients with RET fusion-positive thyroid cancer who were RAI-refractory and had received sorafenib, lenvatinib, or both, in separate cohorts.

The median age was 54 years (range 20 to 88); 52% were male; 74% were White, 11% were Hispanic/Latino, 7.4% were Asian, and 3.7% were Black. ECOG performance status was 0–1 (89%) or 2 (11%). All (100%) patients had metastatic disease with primary tumor histologies including papillary thyroid cancer (78%), poorly differentiated thyroid cancer (11%), anaplastic thyroid cancer (7%) and Hurthle cell thyroid cancer (4%). Patients had received a median of 3 prior therapies (range 1–7). RET fusion-positive status was detected in 93% of patients using NGS tumor samples and in 7% using blood samples.

Efficacy results for RET fusion-positive thyroid cancer are summarized in Table 13.

Table 13: Efficacy Results in LIBRETTO-001 (RET Fusion-Positive Thyroid Cancer)

<table>
<thead>
<tr>
<th></th>
<th>RETEVMO Previously Treated (n = 19)</th>
<th>RETEVMO Systemic Therapy Naïve (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Response Rate¹ (95% CI)</td>
<td>79% (54%, 94%)</td>
<td>100% (63%, 100%)</td>
</tr>
<tr>
<td>Complete response</td>
<td>5.3%</td>
<td>12.5%</td>
</tr>
<tr>
<td>Partial response</td>
<td>74%</td>
<td>88%</td>
</tr>
</tbody>
</table>

Duration of Response

<table>
<thead>
<tr>
<th></th>
<th>18.4 (7.6, NE)</th>
<th>NE (NE, NE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% with ≥6 months²</td>
<td>87</td>
<td>75</td>
</tr>
</tbody>
</table>
19

**14.4 Other RET Fusion-Positive Solid Tumors**

The efficacy of RETEVMO was evaluated in patients with locally advanced or metastatic RET fusion-positive solid tumors enrolled in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001, NCT03157128). Efficacy was evaluated in 41 patients with RET fusion-positive tumors other than NSCLC and thyroid cancer with disease progression on or following prior systemic treatment or who had no satisfactory alternative treatment options.

The median age was 50 years (range 21 to 85), 54% were female, 68% were White, 24% were Asian, and 4.9% were Black; 7% were Hispanic/Latino. ECOG performance status was 0-1 (95%) or 2 (5%) and 95% of patients had metastatic disease. Thirty-seven patients (90%) received prior systemic therapy (median 2 [range 0 – 9]; 32% received 3 or more). The most common cancers were pancreatic adenocarcinoma (27%), colorectal (24%), salivary (10%) and unknown primary (7%). RET fusion-positive status was detected in 97.6% of patients using NGS and 2.4% using FISH.

Efficacy results for RET fusion-positive solid tumors other than NSCLC and thyroid cancer are summarized in Table 14 and Table 15.

**Table 14: Efficacy Results in LIBRETTO-001 (Other RET Fusion-Positive Solid Tumors)**

<table>
<thead>
<tr>
<th>RETEVMO (n = 41)</th>
<th><strong>Overall Response Rate</strong>¹ (95% CI)</th>
<th><strong>Duration of Response</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Complete response</strong></td>
<td><strong>Median in months (95% CI)</strong></td>
</tr>
<tr>
<td></td>
<td>4.9%</td>
<td>24.5 (9.2, NE)</td>
</tr>
<tr>
<td></td>
<td><strong>Partial response</strong></td>
<td><strong>% with ≥6 months²</strong></td>
</tr>
<tr>
<td></td>
<td>39%</td>
<td>67%</td>
</tr>
</tbody>
</table>

¹ Confirmed overall response rate assessed by BIRC.

² Based on observed duration of response.

NE = not estimable

**Table 15: Efficacy Results by Tumor Type in LIBRETTO-001 (Other RET Fusion-Positive Solid Tumors)**

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Patients (n = 41)</th>
<th>ORR¹,²</th>
<th>DOR Range (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>95% CI</td>
<td></td>
</tr>
<tr>
<td>Pancreatic adenocarcinoma</td>
<td>11</td>
<td>6 (55%)</td>
<td>2.5, 38.3+</td>
</tr>
<tr>
<td>Colorectal</td>
<td>10</td>
<td>2 (20%)</td>
<td>5.6, 13.3</td>
</tr>
<tr>
<td>Salivary</td>
<td>4</td>
<td>2 (50%)</td>
<td>5.7, 28.8+</td>
</tr>
<tr>
<td>Unknown primary</td>
<td>3</td>
<td>1 (33%)</td>
<td>9.2</td>
</tr>
<tr>
<td>Breast</td>
<td>2</td>
<td>PR, CR</td>
<td>NA</td>
</tr>
<tr>
<td>Sarcoma (soft tissue)</td>
<td>2</td>
<td>PR, SD</td>
<td>2.3+, 17.3</td>
</tr>
<tr>
<td>Xanthogranuloma</td>
<td>2</td>
<td>NE, NE</td>
<td>NA</td>
</tr>
<tr>
<td>Carcinoid (bronchial)</td>
<td>1</td>
<td>PR</td>
<td>24.1+</td>
</tr>
<tr>
<td>Carcinoma of the skin</td>
<td>1</td>
<td>NE</td>
<td>NA</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>1</td>
<td>PR</td>
<td>5.6+</td>
</tr>
<tr>
<td>Ovarian</td>
<td>1</td>
<td>PR</td>
<td>14.5+</td>
</tr>
<tr>
<td>Pulmonary carcinosarcoma</td>
<td>1</td>
<td>NE</td>
<td>NA</td>
</tr>
</tbody>
</table>
+ denotes ongoing response.
1 Confirmed overall response rate assessed by BIRC.
2 Best overall response for each patient is presented for tumor types with ≤2 patients.
CI = confidence interval, CR = complete response, DOR = duration of response, NA = not applicable, NE = not evaluable, ORR = overall response rate, PR = partial response, SD = stable disease.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

#### How Supplied
RETevaM capsules are supplied as follows:

<table>
<thead>
<tr>
<th>Capsule Strength</th>
<th>Description</th>
<th>Package Configuration</th>
<th>NDC Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 mg</td>
<td>Gray opaque, imprinted with “Lilly”, “3977” and “40 mg” in black ink</td>
<td>60 count bottle</td>
<td>NDC 0002-3977-60</td>
</tr>
<tr>
<td>80 mg</td>
<td>Blue opaque, imprinted with “Lilly”, “2980” and “80 mg” in black ink</td>
<td>60 count bottle</td>
<td>NDC 0002-2980-60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>120 count bottle</td>
<td>NDC 0002-2980-26</td>
</tr>
</tbody>
</table>

RETevaM tablets are supplied in bottles with desiccant in the following configurations:

<table>
<thead>
<tr>
<th>Tablet Strength</th>
<th>Description</th>
<th>Package Configuration</th>
<th>NDC Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 mg</td>
<td>Light gray, film coated, round tablets debossed with “Ret 40” on one side and “5340” on the other side</td>
<td>60 count bottle</td>
<td>NDC 0002-5340-60</td>
</tr>
<tr>
<td>80 mg</td>
<td>Dark red-purple, film coated, round tablets debossed with “Ret 80” on one side and “6082” on the other side</td>
<td>60 count bottle</td>
<td>NDC 0002-6082-60</td>
</tr>
<tr>
<td>120 mg</td>
<td>Light purple, film coated, round tablets debossed with “Ret 120” on one side and “6120” on the other side</td>
<td>60 count bottle</td>
<td>NDC 0002-6120-60</td>
</tr>
<tr>
<td>160 mg</td>
<td>Light pink, film coated, round tablets debossed with Ret “160” on one side and “5562” on the other side</td>
<td>60 count bottle</td>
<td>NDC 0002-5562-60</td>
</tr>
</tbody>
</table>

#### Storage and Handling
Store at 20°C to 25°C (68°F to 77°F); excursions between 15°C and 30°C (59°F to 86°F) are permitted [see USP Controlled Room Temperature].

### 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

**Hepatotoxicity**
Advise patients that hepatotoxicity can occur and to immediately contact their healthcare provider for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.1)].

**Interstitial Lung Disease (ILD)/Pneumonitis**
Advise patients that ILD/ pneumonitis can occur and to contact their healthcare provider immediately for signs or symptoms of ILD including new or worsening cough or shortness of breath [see Warnings and Precautions (5.2)].

**Hypertension**
Advise patients that they will require regular blood pressure monitoring and to contact their healthcare provider if they experience symptoms of increased blood pressure or elevated readings [see Warnings and Precautions (5.3)].

**QT Prolongation**

Advise patients that RETEVMO can cause QTc interval prolongation and to inform their healthcare provider if they have any QTc interval prolongation symptoms, such as syncope [see Warnings and Precautions (5.4)].

**Hemorrhagic Events**

Advise patients that RETEVMO may increase the risk for bleeding and to contact their healthcare provider if they experience any signs or symptoms of bleeding [see Warnings and Precautions (5.5)].

**Hypersensitivity Reactions**

Advise patients to monitor for signs and symptoms of hypersensitivity reactions, particularly during the first month of treatment [see Warnings and Precautions (5.6)].

**Tumor Lysis Syndrome**

Advise patients to contact their healthcare provider promptly to report any signs and symptoms of TLS [see Warnings and Precautions (5.7)].

**Risk of Impaired Wound Healing**

Advise patients that RETEVMO may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure [see Warnings and Precautions (5.8)].

**Hypothyroidism**

Advise patients that RETEVMO can cause hypothyroidism and to immediately contact their healthcare provider for signs or symptoms of hypothyroidism [see Warnings and Precautions (5.9)].

**Embryo-Fetal Toxicity**

Advise pregnant women and females of reproductive potential of the possible risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.10), Use in Specific Populations (8.1)].

Advise females of reproductive potential to use effective contraception during the treatment with RETEVMO and for 1 week after the last dose [see Use in Specific Populations (8.3)].

Advise males with female partners of reproductive potential to use effective contraception during treatment with RETEVMO and for 1 week after the last dose [see Use in Specific Populations (8.3)].

**Lactation**

Advise women not to breastfeed during treatment with RETEVMO and for 1 week after the last dose [see Use in Specific Populations (8.2)].

**Infertility**

Advise males and females of reproductive potential that RETEVMO may impair fertility [see Use in Specific Populations (8.4), Nonclinical Toxicology (13.1)].

**Drug Interactions**

Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John’s wort, proton pump inhibitors, H2 receptor antagonists, and antacids while taking RETEVMO.

If PPIs are required, instruct patients to take RETEVMO with food. If H2 receptor antagonists are required, instruct patients to take RETEVMO 2 hours before or 10 hours after the H2 receptor antagonist. If locally-acting antacids are required, instruct patients to take RETEVMO 2 hours before or 2 hours after the locally-acting antacid [see Drug Interactions (7.1, 7.2)].